Literature DB >> 1322218

Paralytic poliomyelitis in England and Wales, 1985-91.

R Joce1, D Wood, D Brown, N Begg.   

Abstract

OBJECTIVES: To ascertain all cases of paralytic poliomyelitis in England and Wales during 1985-91 and to determine the source of infection in each case.
DESIGN: Descriptive study of cases reported between 1985 and 1991.
SETTING: All health districts in England and Wales.
SUBJECTS: Patients normally resident in England and Wales whose clinical features were consistent with paralytic poliomyelitis or with laboratory evidence of recent poliovirus infection and compatible symptoms. MAIN OUTCOME MEASURES: Clinical, epidemiological, and laboratory features in identified cases.
RESULTS: Of 54 suspected cases of poliomyelitis, 33 were excluded, leaving 21 cases, of which 13 were vaccine associated (nine recipient and four contact) cases, five were imported cases, and three were cases whose source of infection was unknown. No cases due to indigenous wild polioviruses were identified; two were imported cases due to wild viruses. One patient died during the acute phase of the illness, and two children with previously unrecognised severe congenital immune deficiency died between one and two months after the onset of paralysis after the first or second dose of oral polio vaccine. The estimated risk of vaccine associated paralysis is 1.46 per million for the first dose, 0.49 for the second, zero for the third and fourth doses, and 0.33 for the fifth.
CONCLUSIONS: Indigenous wild poliovirus seems to have been eradicated, although wild virus may be imported; improved surveillance of suspected cases including immediate notification and characterisation of the virus to ensure that eradication is maintained is essential.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1322218      PMCID: PMC1882611          DOI: 10.1136/bmj.305.6845.79

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


  8 in total

1.  Intratypic serodifferentiation of poliomyelitis virus strains by strain-specific antisera.

Authors:  A L van Wezel; A G Hazendonk
Journal:  Intervirology       Date:  1979       Impact factor: 1.763

2.  The British Paediatric Surveillance Unit.

Authors:  S M Hall; M Glickman
Journal:  Arch Dis Child       Date:  1988-03       Impact factor: 3.791

3.  Diagnosis of poliomyelitis by demonstration of intrathecal synthesis of neutralizing antibodies.

Authors:  T Hovi; M Stenvik; E Kinnunen
Journal:  J Infect Dis       Date:  1986-05       Impact factor: 5.226

4.  Prevalence of antibody to poliovirus in England and Wales 1984-6.

Authors:  P M White; J Green
Journal:  Br Med J (Clin Res Ed)       Date:  1986-11-01

5.  Importation of poliomyelitis to industrialised nations between 1975 and 1984: evaluation and conclusions for vaccination recommendations.

Authors:  D Kubli; R Steffen; M Schär
Journal:  Br Med J (Clin Res Ed)       Date:  1987-07-18

6.  Increased neurovirulence associated with a single nucleotide change in a noncoding region of the Sabin type 3 poliovaccine genome.

Authors:  D M Evans; G Dunn; P D Minor; G C Schild; A J Cann; G Stanway; J W Almond; K Currey; J V Maizel
Journal:  Nature       Date:  1985 Apr 11-17       Impact factor: 49.962

7.  Paralytic poliomyelitis in England & Wales, 1970-84.

Authors:  N T Begg; R Chamberlain; M Roebuck
Journal:  Epidemiol Infect       Date:  1987-08       Impact factor: 2.451

8.  Paralytic poliomyelitis in England and Wales 1976-7.

Authors:  K E Collingham; T M Pollock; M O Roebuck
Journal:  Lancet       Date:  1978-05-06       Impact factor: 79.321

  8 in total
  22 in total

1.  Eradication of poliomyelitis.

Authors:  S C Arya
Journal:  BMJ       Date:  1992-09-12

2.  Polio immunity in Ontario.

Authors:  Subhash C Arya; Nirmala Agarwal
Journal:  CMAJ       Date:  2010-11-09       Impact factor: 8.262

3.  Polio eradication as 2000 approaches.

Authors:  A J Hall
Journal:  BMJ       Date:  1992-07-11

4.  Apropos "seroprevalence of antipolio antibodies among children <15 years of age in border provinces in China".

Authors:  Subhash C Arya; Nirmala Agarwal
Journal:  Clin Vaccine Immunol       Date:  2013-10

5.  Rare disease surveillance: An international perspective.

Authors:  E J Elliott; A Nicoll; R Lynn; V Marchessault; R Hirasing; G Ridley
Journal:  Paediatr Child Health       Date:  2001-05       Impact factor: 2.253

6.  Polio vaccine: is it time for a change?

Authors:  A Finn; F Bell
Journal:  Arch Dis Child       Date:  1998-06       Impact factor: 3.791

7.  Outbreak of poliomyelitis in Albania and neighboring countries in 1996.

Authors:  A Arya
Journal:  J Clin Microbiol       Date:  1999-01       Impact factor: 5.948

8.  Acute paralytic illness.

Authors:  D Kidd; H Manji; D Brown; R S Howard
Journal:  Postgrad Med J       Date:  1996-11       Impact factor: 2.401

9.  Role of mutations G-480 and C-6203 in the attenuation phenotype of Sabin type 1 poliovirus.

Authors:  A McGoldrick; A J Macadam; G Dunn; A Rowe; J Burlison; P D Minor; J Meredith; D J Evans; J W Almond
Journal:  J Virol       Date:  1995-12       Impact factor: 5.103

10.  Risk of vaccine-associated paralytic poliomyelitis in Latin America, 1989-91.

Authors:  J K Andrus; P M Strebel; C A de Quadros; J M Olivé
Journal:  Bull World Health Organ       Date:  1995       Impact factor: 9.408

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.